KELOWNA, BC / ACCESSWIRE / April 24, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP) (OTCQB:TRYPF) is pleased to announce that the shareholders of Exopharm Limited ACN 163 765 991 (" Exopharm ") have approved the previously announced plan of arrangement (the " Arrangement ") between the parties. The Company is also pleased to confirm that all conditions precedent to the completion of the Arrangement have... Read More

KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP) (OTCQB:TRYPF) is pleased to announce that the Company's securityholders overwhelmingly approved the previously announced arrangement (the " Arrangement ") involving the Company and Exopharm Limited CAN 163 765 991 at the Company's annual general and special meeting of securityholders (the " Meeting ") held on March 8,... Read More

KELOWNA, BC / ACCESSWIRE / February 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP) (OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that further to its press releases of December 11, 2023 and January 26, 2024, Tryp has obtained an interim... Read More

KELOWNA, BC / ACCESSWIRE / January 26, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that in a strategic move to foster a robust market for their combined entity, Tryp and Exopharm Limited have... Read More

KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP )( OTCQB:TRYPF ), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,today announced a significant milestone in its clinical trial program for TRP-8803 (IV-infused psilocin). The Company... Read More

KELOWNA, BC / ACCESSWIRE / January 4, 2024 / Tryp Therapeutics Inc. (" Tryp " or the " Company ") ( CSE:TRYP ), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that the first patient has been dosed in a Phase 2a clinical trial being conducted by the University of Michigan in a... Read More

KELOWNA, BC / ACCESSWIRE / November 20, 2023 / Tryp Therapeutics Inc. (" Tryp " or the " Company ") ( CSE:TRYP ), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that it has closed its previously announced private placement (the " PrivatePlacement ") of unsecured convertible notes... Read More

KELOWNA, BC / ACCESSWIRE / October 11, 2023 / Tryp Therapeutics Inc. (" Tryp " or the " Company ") ( CSE:TRYP ), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that it has closed its previously announced private placement (the " Private Placement ") of unsecured convertible... Read More

KELOWNA, BC / ACCESSWIRE / August 3, 2023 / Tryp Therapeutics Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company dedicated to developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased to announce the appointment of Australia-based Jason Carroll as the Company's new Chief Executive Officer, beginning October... Read More

KELOWNA, BC / ACCESSWIRE / August 2, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), announces with deep regret the passing of Mr. David Tousley, Director of Tryp and Chair of Tryp's Audit Committee. Dave was a highly experienced director who provided the Board with consistent, sage advice. His input was always well-reasoned and practical on issues brought to the Board. He worked tirelessly... Read More

KELOWNA, BC / ACCESSWIRE / July 13, 2023 / Tryp Therapeutics , Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced it has received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Tryp's Investigational... Read More

KELOWNA, BC / ACCESSWIRE / May 24, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its... Read More

KELOWNA, BC / ACCESSWIRE / April 27, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that it has closed its previously announced private placement (the " Private Placement ") of secured convertible debentures (the... Read More

KELOWNA, BC / ACCESSWIRE / April 4, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced it has completed the training of psychotherapists for its planned Phase 2a clinical trial investigating the effects of... Read More

Interim data analysis supports the potential effectiveness of psilocybin-assisted psychotherapy for the treatment of Binge Eating Disorder TRP-8802 demonstrated significant and prolonged improvement in primary endpoints for all five patients Across all patients treated with TRP-8802, daily binge eating episodes were reduced by an average of 80.4% from baseline during the four-week post-dosing measurement period, with all... Read More

KELOWNA, BC / ACCESSWIRE / January 3, 2023 / Tryp Therapeutics , Inc. (CSE:TRYP) (OTCQB:TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced the signing of a letter of intent with Massachusetts General Hospital (MGH), the largest teaching hospital of... Read More

KELOWNA, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that the Company will be presenting at the Biotech Showcase on Monday, January 9, 2023, at the Hilton San Francisco Union... Read More

KELOWNA, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today reported on corporate highlights from 2022 and announced the filing of its audited financial statements for the fiscal year ending August... Read More

KELOWNA, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company’s collaborators from the University of Michigan will present two scientific posters in the upcoming Society for Neuroscience... Read More

Enables Potentially Scalable Model For The Broad Roll-Out of Psychedelic Treatments Company Will Host Investor Update Tuesday, October 4 th Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the World Intellectual Property Organization (WIPO)... Read More

Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. One patent application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other application,... Read More

Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the retention of IMS Investor Relations (“ IMS ”) effective August 15, 2022. IMS will provide capital markets consulting, corporate communications and strategic investor outreach. Jim Gilligan, Chief... Read More

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announces that it has completed a third tranche of its private placement (the " Private Placement ") previously announced on February 4, 2022 , February 17, 2022 and April 22, 2022 for aggregate gross proceeds of $150,000... Read More

Biotech Company Strengthens Strategic Intellectual Property Protection of Targeted Indication Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of a new provisional patent for the use of psilocybin for the treatment of patients with Binge Eating... Read More

Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that Sid Taubenfeld , a... Read More

Initial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatment of Binge Eating Disorder Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the initial data readout for the first patient dosed in... Read More

Industry leader Chris Ntoumenopoulos to support biotech Company's mission to advance the delivery of psychedelic medicines Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Chris Ntoumenopoulos to the Company's Board of Directors. "Chris... Read More

Phase II trial to determine efficacy of psilocybin in combination with psychotherapy for potential treatment of Binge Eating Disorder Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet... Read More

Tryp Therapeutics (CSE:TRYP) (OTC:TRYPF) (“ Tryp ” or the “ Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announces that it has amended the terms of its private placement (the “ Private Placement ”) previously announced on February 4, 2022 and February 17, 2022. The Company also announces the closing of a second tranche of the Private Placement... Read More

Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders Tryp Therapeutics , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the first patient enrolled to evaluate its clinical candidate, TRP-8802, in a clinical trial. The study will investigate the safety and preliminary... Read More

Recognized industry leader brings deep finance and operational experience to Tryp board Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, is pleased to announce that Mr. David L. Tousley , CPA, MBA, has been appointed as a new independent director to replace William Garner , M.D., who... Read More

REVISED DEAL INCLUDES INCREASE IN PREMIUM SHARE PRICE TO $0.20 PER SHARE WITHOUT WARRANTS PRIVATE PLACEMENT GROSS PROCEEDS OF UP TO $6 MILLION WITH $4 MILLION LEAD ORDER SECURED FROM TRYP CO-FOUNDER, DR. WILLIAM GARNER Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, is pleased to... Read More

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech Showcase. The events will be held virtually on January 10-12, 2022. Greg McKee , Chairman and CEO of Tryp, will provide an overview of... Read More

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the receipt of correspondence from the U.S. Food and Drug Administration (FDA) affirming the Company's ability to proceed with... Read More

Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) (" Tryp " or the " Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received confirmation from the U.S. Food and Drug Administration (" FDA ") that its review of Tryp's... Read More

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of its audited financial statements for the fiscal year ending August 31, 2021 and reported on corporate... Read More

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present at the 2 nd Annual H.C. Wainwright Psychedelics Conference. The conference will be held virtually on... Read More

Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) (" Tryp " or the " Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received confirmation from the U.S. Food and Drug Administration (" FDA ") that its review of Tryp's... Read More

Tryp Therapeutics (CSE:TRYP;OTCQB:TRYPF) (" Tryp " or the " Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received correspondence from the U.S. Food and Drug Administration (" FDA ") related to the Company's... Read More

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that the Company will participate in Wonderland: Miami, presented by Microdose, on November 8, 2021. The conference will take place on November 8-9, 2021 in Miami, Florida. Greg McKee, Chairman and CEO, will participate in... Read More

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug (" IND ") application to the U.S. Food and Drug Administration (" FDA ") to evaluate its clinical candidate, TRP-8802, in a Phase 2a clinical trial that investigates safety... Read More

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company will present at the 15 th Annual Pain Therapeutics Summit on November 1, 2021 at 12:15 p.m. EDT. The virtual conference will take place on November 1-3, 2021. Greg McKee, Chairman and CEO, will provide an... Read More